🇺🇸 FDA
Patent

US 11352428

Modulation of immune response using BTLA agonist antibodies

granted A61KA61K2039/505A61P

Quick answer

US patent 11352428 (Modulation of immune response using BTLA agonist antibodies) held by SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Grant date
Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/505, A61P, A61P29/00, A61P37/00